High Dose BAYA1040 CR: a Long Term Extension Study

Summary

This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8 week double blind treatment phase of Study 13176.

Timeline

Start

2011-01

Primary completion

2011-09

Completion

2012-04

Drugs

Indications